Prognostic and Diagnostic Added Value of Medical Imaging in Gynecological Cancer (PRODIGYN)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorRegion Västerbotten
About this trial
The goal of this observational study is to learn about the added diagnostic and prognostic value of advanced medical imaging procedures in cervical cancer, endometrial cancer and ovarian cancer. The main questions it aims to answer are:
* Does advanced medical imaging predict survival? * Can advanced medical imaging improve radiotherapy target planning? * Are advanced medical imaging results associated with risk markers found in tumor tissue?
Participants will
* Undergo four additional imaging procedures, as compared to clinical routine examinations, two at baseline and two after three months. * Be subject to clinical follow-up for five years.
Eligibility criteria
Qualifiers
Previously untreated primary cervical, endometrial, or strongly suspected epithelial ovarian cancer.
Known clinical FIGO stage.
>18 years old.
No other known current or previous malignancy within the last 10 years.
Disqualifiers
Imaging findings suggestive of other primary malignancy.
Previously included suspected epithelial ovarian cancer, later confirmed to be other diagnosis than epithelial ovarian cancer or "cancer abdominis".
MRI incompatible devices or patient unable to undergo MRI.
Trial design
Treatments tested in this trial
- FDG-PET/CT and FDG-PET/MRI
Treatment groups
120 Participants
are divided into 3 treatment groupsSponsors and collaborators
Region Västerbotten
Lead sponsor
Umeå University
Collaborator
Source ClinicalTrials.gov